PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1759000
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1759000
Global Biomanufacturing Viral Detection and Quantifications Market to Reach US$793.2 Million by 2030
The global market for Biomanufacturing Viral Detection and Quantifications estimated at US$547.8 Million in the year 2024, is expected to reach US$793.2 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Consumables Offering, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$464.1 Million by the end of the analysis period. Growth in the Instruments Offering segment is estimated at 8.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$149.2 Million While China is Forecast to Grow at 9.8% CAGR
The Biomanufacturing Viral Detection and Quantifications market in the U.S. is estimated at US$149.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$161.3 Million by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
Global Biomanufacturing Viral Detection and Quantifications Market - Key Trends & Drivers Summarized
Why Is Viral Detection and Quantification Crucial in Biomanufacturing Today?
In the field of biomanufacturing, viral detection and quantification have become indispensable processes, ensuring the safety, quality, and efficacy of biologically-derived products. Biologics, such as monoclonal antibodies, gene therapies, vaccines, and recombinant proteins, are often produced using living cell systems that can be vulnerable to viral contamination during development, production, or packaging stages. Even trace amounts of adventitious viruses-whether from raw materials, host cells, or the production environment-can compromise entire product batches, lead to regulatory non-compliance, and pose serious health risks to patients. Therefore, comprehensive viral safety strategies involving both detection (identifying the presence of viruses) and quantification (measuring viral load or titer) are critical to biomanufacturing workflows. These processes help ensure that final biopharmaceutical products are free from both known and emerging viral contaminants. Regulatory agencies such as the FDA, EMA, and WHO mandate rigorous viral safety testing and validation throughout the development lifecycle, making this area not just a technical necessity but a legal imperative. Moreover, with the rise of complex biologics and personalized therapies-especially cell and gene therapies-the sensitivity and accuracy of viral detection systems must evolve accordingly. In this environment, reliable viral monitoring has become a cornerstone of manufacturing assurance, product consistency, and public health protection in the biopharma sector.
How Are Innovations in Detection Technologies Improving Viral Safety in Biomanufacturing?
Technological advancements are significantly enhancing the accuracy, speed, and sensitivity of viral detection and quantification in biomanufacturing. Traditional methods such as in vivo animal testing and in vitro cell culture assays, while still important, are increasingly being complemented or replaced by modern molecular techniques. Real-time quantitative polymerase chain reaction (qPCR) and digital PCR have become gold standards for their ability to detect and quantify specific viral genomes with high precision and rapid turnaround times. Additionally, next-generation sequencing (NGS) technologies are revolutionizing viral detection by enabling unbiased identification of both known and novel viral contaminants, thereby strengthening safety in early and late-stage manufacturing. These techniques offer high-throughput, deep-sequencing capabilities that allow for comprehensive viral surveillance at the genetic level. Advances in bioinformatics are further empowering researchers to analyze massive datasets quickly, identifying viral signatures even at very low concentrations. Other innovations include biosensors using surface plasmon resonance (SPR), immunoassays with enhanced monoclonal antibody specificity, and mass spectrometry techniques that profile viral proteins. Automation and digitalization of testing workflows are reducing manual errors and ensuring consistency across batches. Artificial intelligence is also being leveraged to predict contamination risks and optimize detection protocols. These cutting-edge technologies not only improve detection limits and reduce false positives/negatives but also facilitate real-time, in-line monitoring during biomanufacturing, enabling faster corrective actions. As a result, these innovations are raising the standard of viral safety across the biomanufacturing industry and creating robust systems to support high-stakes therapeutic production.
Which Sectors and Geographies Are Leading the Push for Viral Safety in Biomanufacturing?
The demand for effective viral detection and quantification in biomanufacturing is being driven by multiple sectors, with the pharmaceutical and biotechnology industries at the forefront. Companies producing biologics-especially monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines-have the highest need for stringent viral monitoring protocols. This is particularly true for gene therapy vectors like AAVs (adeno-associated viruses) and lentiviruses, which require exact quantification to ensure safety, dose consistency, and therapeutic efficacy. CDMOs (contract development and manufacturing organizations) also play a key role, offering viral safety testing as a critical service for smaller biotech firms and clinical-stage developers. In addition to pharma, the diagnostics industry is increasingly focused on viral quantification, especially for products involving viral reagents or derived from cell cultures. Geographically, North America leads the market, bolstered by its advanced biomanufacturing infrastructure, strong regulatory oversight, and heavy investments in biologic development. The U.S., home to the FDA and many leading biotech firms, sets global standards for viral safety. Europe follows closely, driven by the EMA’s stringent quality regulations and a mature biologics ecosystem in countries like Germany, the UK, and Switzerland. Asia-Pacific, particularly China, South Korea, India, and Japan, is experiencing rapid growth in biomanufacturing capabilities and is investing heavily in quality control to meet global export standards. These regions are also ramping up domestic biologic production, further fueling the demand for viral safety assurance. Globally, the expansion of pandemic preparedness initiatives and the rise of biologics across emerging markets are broadening the geographic scope of demand for viral detection and quantification.
What Is Fueling the Growth in the Global Biomanufacturing Viral Detection and Quantifications Market?
The growth in the global biomanufacturing viral detection and quantifications market is driven by several key factors: the increasing production of complex biologics, rising regulatory scrutiny, growing incidence of viral outbreaks, and ongoing advancements in detection technologies. One of the primary growth drivers is the expanding pipeline of biologic drugs and advanced therapies-particularly gene and cell therapies-which require meticulous viral safety monitoring at every stage. These treatments often involve viral vectors or are produced in viral-prone environments, making sensitive detection and precise quantification absolutely critical. Regulatory agencies are tightening viral safety requirements, pushing manufacturers to adopt the latest, most robust testing methodologies. High-profile recalls and contamination incidents have also increased awareness of viral risks, leading to greater investment in preventive quality control. Another major growth factor is the global focus on pandemic preparedness and biosurveillance following the COVID-19 crisis, which exposed vulnerabilities in biological supply chains. This has accelerated demand for fast, scalable viral detection systems not just for finished products, but also for raw materials and process intermediates. Technological innovation-particularly in digital PCR, NGS, and AI-based analytics-is lowering testing costs, improving accessibility, and making it easier to integrate viral monitoring into continuous bioprocessing environments. Furthermore, the globalization of biomanufacturing and the rise of CDMOs are extending viral detection requirements to new markets and facilities worldwide. These trends are also supported by strategic partnerships between diagnostics companies, regulatory bodies, and academic institutions aimed at standardizing protocols and developing universal detection frameworks. Altogether, these drivers are ensuring that viral detection and quantification remain indispensable to the safe, scalable, and compliant production of biologics in the years ahead.
SCOPE OF STUDY:
The report analyzes the Biomanufacturing Viral Detection and Quantifications market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Offering (Consumables Offering, Instruments Offering, Services Offering); Technology (PCR Technology, ELISA Technology, Flow Cytometry Technology, Plaque Assay Technology, Other Technologies); Application (Blood & Blood Products Manufacturing Application, Vaccines & Therapeutics Manufacturing Application, Cellular & Gene Therapy Products Manufacturing Application, Stem Cell Products Manufacturing Application, Tissue & Tissue Products Manufacturing Application); End-Use (Life Science Companies End-Use, Testing Laboratories End-Use, CROs & CDMOs End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 43 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.